175 related articles for article (PubMed ID: 37902466)
21. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
Zeuzem S; Sulkowski MS; Lawitz EJ; Rustgi VK; Rodriguez-Torres M; Bacon BR; Grigorescu M; Tice AD; Lurie Y; Cianciara J; Muir AJ; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
Gastroenterology; 2010 Oct; 139(4):1257-66. PubMed ID: 20600013
[TBL] [Abstract][Full Text] [Related]
22. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
23. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
Dogan UB; Golge N; Akin MS
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
25. Nb-UVB and PUVA therapy in treating early stages of Mycosis Fungoides: A single-center cross-sectional study.
Zengarini C; Baruffaldi G; Piraccini BM; Bardazzi F; Mussi M; Hrvatin Stancic B; Pileri A
Photodermatol Photoimmunol Photomed; 2023 Sep; 39(5):435-440. PubMed ID: 36974002
[TBL] [Abstract][Full Text] [Related]
26. Optimal combination with PUVA: rationale and clinical trial update.
Stadler R
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
[TBL] [Abstract][Full Text] [Related]
27. Systematic review of combination therapies for mycosis fungoides.
Humme D; Nast A; Erdmann R; Vandersee S; Beyer M
Cancer Treat Rev; 2014 Sep; 40(8):927-33. PubMed ID: 24997678
[TBL] [Abstract][Full Text] [Related]
28. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium.
Olsen EA; Hodak E; Anderson T; Carter JB; Henderson M; Cooper K; Lim HW
J Am Acad Dermatol; 2016 Jan; 74(1):27-58. PubMed ID: 26547257
[TBL] [Abstract][Full Text] [Related]
29. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
[TBL] [Abstract][Full Text] [Related]
30. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
[TBL] [Abstract][Full Text] [Related]
31. Roferon-A in combination with Tigason in cutaneous T-cell lymphomas.
Dreno B; Celerier P; Litoux P
Acta Haematol; 1993; 89 Suppl 1():28-32. PubMed ID: 8475670
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
33. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
Duvic M
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
[TBL] [Abstract][Full Text] [Related]
34. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
Dummer R; Garbe C; Thompson JA; Eggermont AM; Yoo K; Maier T; Bergstrom B
J Clin Oncol; 2006 Mar; 24(7):1188-94. PubMed ID: 16505439
[TBL] [Abstract][Full Text] [Related]
35. Treatment of cutaneous T cell lymphoma: current status and future directions.
Apisarnthanarax N; Talpur R; Duvic M
Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
[TBL] [Abstract][Full Text] [Related]
36. [Photodynamic therapy of cutaneous T-cell lymphoma at special sites].
Eich D; Eich HT; Otte HG; Ghilescu V; Stadler R
Hautarzt; 1999 Feb; 50(2):109-14. PubMed ID: 10097953
[TBL] [Abstract][Full Text] [Related]
37. Phototherapy for Cutaneous T-Cell Lymphoma.
Marka A; Carter JB
Dermatol Clin; 2020 Jan; 38(1):127-135. PubMed ID: 31753185
[TBL] [Abstract][Full Text] [Related]
38. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
[TBL] [Abstract][Full Text] [Related]
39. Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.
Wu PA; Huang V; Bigby ME
Br J Dermatol; 2014 May; 170(5):1015-20. PubMed ID: 24841586
[TBL] [Abstract][Full Text] [Related]
40. Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation.
Chan WH; Lewis DJ; Hinojosa T; Curry JL; Duvic M
Pediatr Dermatol; 2018 Jan; 35(1):e13-e16. PubMed ID: 29159918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
